Carine Bokop Fotso

Ms. Carine Bokop Fotso

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CFCarine Bokop Fotso
Carine Bokop Fotso
NDNisha Dhar
Nisha Dhar
AIAlane Izu
Alane Izu
MAMusa Mohammed Ali
Musa Mohammed Ali
GAGodwin Akaba
Godwin Akaba
GKGaurav Kwatra
Gaurav Kwatra
To investigate the transplacental acquisition of measles IgG in newborn at delivery in Bangladesh, Bhutan, India, Ethiopia, Mozambique, Kenya, Nigeria, Mali, and South Africa. Archived cord serum, from a multi-center study on Group B Streptococcus, were tested for measles IgG using a commercial enzyme link immunosorbent assay (ELISA). We tested 323 randomly selected samples from each of the sites. Models using various measles antibody decay rates in infancy were explored. Overall, 2907 cord serum samples were analyzed. At birth, 49.9% of newborns were measles IgG seronegative. Measles seronegativity ranged from 21.7% in Nigeria to 73.4% in Bhutan. The adjusted odds of seronegativity in infants of mothers born after measles vaccination implementation was 1.78 times that for infants born to unvaccinated mothers (aOR, 1.78; 95%CI:1.43-2.21; p <0.001). Modeling measles IgG kinetics predicted 70.8%, 88.3%, and 100% of infants would be seronegative by two, four, and six months, respectively, without further exposure. Our findings suggest low transplacental acquisition of measles IgG in newborns, which is likely to yield susceptibility to measles infection at a very young age. The currently recommended measles vaccine schedules in LMIC, with the first dose recommended from nine months of age and onward, warrant reconsideration, including the need for earlier dosing schedules.

5 July 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
CFCarine Bokop Fotso
Carine Bokop Fotso
LFLINDIWE MODEST FAYE
LINDIWE MODEST FAYE
TATeke Apalata
Teke Apalata
The study sought to determine the rate of discordant results between genotypic and phenotypic tests for the diagnosis of drug-resistant tuberculosis (DR-TB). Sputum samples and cultured isolates from suspected DR-TB patients were, respectively, analyzed for Mycobacterium tuberculosis by Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) and line probe assays (LPA) (Hain, Nehren, Germany). Discrepant rifampicin (RMP)-resistant results were confirmed using BACTEC MGIT960 (BD, New York, NY, USA). Of the 224 RMP-resistant results obtained by Xpert MTB/RIF, 5.4% were susceptible to RMP by LPA. MGIT960 showed a 75% agreement with LPA. The discrepancy was attributed to either heteroresistance or DNA contamination during LPA testing in 58.3% of cases. In 25% of the samples showing agreement in RMP resistance between Xpert MTB/RIF and MGIT960, the discrepancy was attributed to laboratory errors causing false RMP susceptible results with LPA. In 16.7% of the cases, the discrepancy was attributed to false RMP susceptible results with Xpert MTB/RIF. Out of the 224 isolates, susceptibility to isoniazid (INH) by LPA was performed in 73.7% RMP-resistant isolates, of which, 80.6% were resistant. All RMP-resistant isolates by Xpert MTB/RIF were confirmed in 98.5% by LPA if TB isolates were resistant to INH, but were only confirmed in 81.3% if TB isolates were susceptible to INH (p < 0.001). In conclusion, laboratory errors should be considered when investigating discordant results.

6 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
CFCarine Bokop Fotso
Carine Bokop Fotso
LFLINDIWE MODEST FAYE
LINDIWE MODEST FAYE
TATeke Apalata
Teke Apalata
The study sought to determine the rate of discordant results between genotypic and phe-notypic tests for the diagnosis of drug resistant tuberculosis (DR-TB). Sputum samples and cultured isolates from suspected DR-TB patients were respectively analysed for My-cobacterium tuberculosis by Xpert® MTB/RIF (Cepheid, USA) and Line Probe Assays (LPA) (Hain, Germany). Discrepant Rifampicin (RMP) resistant results were confirmed using BACTEC MGIT960 (BD, USA). Of 224 RMP-resistant by Xpert MTB/RIF, 5.4% were suscep-tible to RMP by LPA. MGIT960 showed 75% agreement with LPA. Discrepancy was at-tributed to either heteroresistance or DNA contamination during LPA testing in 58.3% of cases. In 25% of samples showing agreement in RMP resistance between Xpert MTB/RIF and MGIT960, discrepancy was attributed to laboratory errors causing false RMP suscep-tible results with LPA. Of 16.7% of cases, discrepancy was attributed to false RMP suscep-tible results with Xpert MTB/RIF. Of 224 isolates, susceptibility to isoniazid (INH) by LPA was performed in 73.7% RMP resistant isolates, of which, 80.6% were resistant. All RMP resistant isolates by Xpert MTB/RIF were confirmed in 98.5% by LPA if TB isolates were resistant to INH, but only confirmed in 81.3% if TB isolates were INH susceptible (ρ < 0.001). In conclusion, Laboratory errors should be considered when investigating dis-cordant results.

5 September 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
SMSidwell Mvo
Sidwell Mvo
CFCarine Bokop Fotso
Carine Bokop Fotso
BLBenjamin Longo-Mbenza
Benjamin Longo-Mbenza
Sandeep VasaikarSandeep Vasaikar
Sandeep Vasaikar
TATeke Apalata
Teke Apalata
The study sought to determine factors associated with prolonged smear positivity in multidrug-resistant tuberculosis (MDR-TB) patients following appropriate management. Newly diagnosed patients were enrolled between June 2017 and May 2018. Sputum samples were collected for Xpert® MTB/RIF and line probe assays (LiPAs). Microscopic tests were performed at baseline and 4, 8, and 12 weeks post-anti-TB therapy. Of the 200 patients, 114 (57%) were HIV-positive. After 12 weeks of treatment, there was a significant microscopy conversion rate among DS-TB patients compared to MDR-TB patients irrespective of their HIV status (p = 0.0013). All MDR-TB patients who had a baseline smear grade ranging from scanty to +1 converted negative, while 25% ranging from +2 to +3 remained positive until the end of 12 weeks (p = 0.014). Factors associated with smear positivity included age <35 years (p = 0.021), initial CD4+ T-cell count ≥200 cells/mm3 (p = 0.010), and baseline smear grade ≥2+ (p = 0.014). Cox regression showed that only the baseline smear grade ≥2+ was independently associated with prolonged smear positivity in MDR-TB patients (p = 0.011) after adjusting for HIV status, CD4+ T-cell count, and age. Baseline sputum smear grade ≥2+ is a key determinant for prolonged smear positivity beyond 12 weeks of effective anti-TB therapy in MDR-TB patients.